fda warning letter compounding semaglutide october 2025 Navigating Compounded Semaglutide: What Health Care Providers Need to Know October 27, 2025: U.K. regulators

Consideration should be made to stop semaglutide if less than 5% of the initial weight has been lost after 6 months of treatment

The GIP receptor component enhances insulin secretion and may reduce nausea associated with GLP-1 activation

As of July 31, 2025, the FDA reported 605 adverse events linked to compounded semaglutide and 545 for compounded tirzepatide

In the event of GLS or ASNS inhibition, compensatory mechanisms may emerge, potentially accounting for the diminished anticancer efficacy observed in GLS targeting

To translate visual co-localization observed in traditional microscopy into quantifiable physical proximity, the last decade has seen the rapid evolution of genetically encoded contact sensors